Extract
A phase III trial of delamanid showed acceptable safety and tolerability; however, it failed to demonstrate superior efficacy of delamanid in terms of reduction in time to sputum conversion and improvement in final treatment outcomes compared with placebo [1]. How to interpret these results and identify the role of delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment is challenging [2]. Despite the disappointing results, this trial suggests that more studies are needed to better understand the role of delamanid in the current management of MDR-TB. So far, there have been several reports of real-world data on the interim outcomes of delamanid treatment [3–6], but few on its final outcomes [7].
Abstract
The optimised use of delamanid combined with effective repurposed drugs could achieve a high treatment success rate, even in pre-extensively drug-resistant (XDR)-TB and XDR-TB patients http://bit.ly/2plvEOT
Footnotes
Conflict of interest: J. Mok has nothing to disclose.
Conflict of interest: H. Kang has nothing to disclose.
Conflict of interest: W-J. Koh has nothing to disclose.
Conflict of interest: B.W. Jhun has nothing to disclose.
Conflict of interest: J-J. Yim has nothing to disclose.
Conflict of interest: N. Kwak has nothing to disclose.
Conflict of interest: T. Lee has nothing to disclose.
Conflict of interest: B. Kang has nothing to disclose.
Conflict of interest: D. Jeon has nothing to disclose.
- Received April 23, 2019.
- Accepted June 30, 2019.
- Copyright ©ERS 2019
LIBRARY USERS
Log in through your institution
Purchase access
